In a recent clinical trial, researchers have found promising clinical activity of Pembrolizumab with Trastuzumab in patients with PD-L1 positive, Trastuzumab-resistant, advanced HER-2 positive breast cancer (Read more).
As per latest clinical trial results, Ramucirumab improved overall and progression free survival vs placebo in patients with advanced Hepatocellular carcinoma (HCC) & increased alpha-fetoprotein levels previously treated with Sorafenib (Read more).
A recent study suggests that tyrosine kinase inhibitor treatment outcomes for EGFR mutant NSCLCpatients did not differ according to MET high vs MET low status (Read more). MET activation has been implicated as an oncogenic driver in EGFR-mutant disease that can mediate primary and secondary resistance to EGFR tyrosine kinase inhibitors.
Results from a randomized trial showed that first-line therapy with a combination of Pembrolizumab and Axitinib extended both overall survival and progression-free survival for patients with clear cell metastatic Renal Cell Carcinoma (RCC) compared with the current standard of care, Sunitinib (Read more).
In another clinical trial, researchers found that first-line Pembrolizumab produced a high response rate in patients with advanced Merkel cell carcinoma (Read more).
The FDA has granted approval to Pembrolizumab for the adjuvant treatment of patients with Melanomawith involvement of lymph node following complete resection (Read more).
